Literature DB >> 11682505

Application of virus-specific immunoglobulin M (IgM), IgG, and IgA antibody detection with a polyantigenic enzyme-linked immunosorbent assay for diagnosis of Epstein-Barr virus infections in childhood.

L Schaade1, M Kleines, M Häusler.   

Abstract

The Enzygnost anti-Epstein-Barr virus enzyme-linked immunosorbent assay (ELISA) system, which is based on a defined antigen mixture and on detection of antibodies of the immunoglobulin G (IgG), IgM, and IgA classes, was evaluated for its reliability in diagnosing Epstein-Barr virus infections in childhood. With samples from 66 children, the Epstein-Barr virus status and the infection phase were defined by indirect immunofluorescence and anticomplement fluorescence assays: 11 children were seronegative, 8 had a primary infection, 20 had a recent primary or past infection, and in 27 a reactivated Epstein-Barr virus infection was diagnosed. When applying the Enzygnost ELISAs, 15 serum samples (22.7%) were not interpretable due to indeterminate results in at least one of the assays used and were therefore excluded from further evaluation. The respective sensitivities and specificities for the diagnosis of seronegativity were 100 and 100%, those for the diagnosis of primary infection were 100 and 97%, those for the diagnosis of recent primary or past infection were 100 and 52%, and those for the diagnosis of reactivated infection were 10 and 100%. This poor performance of the Enzygnost system with reactivated infections is due to the prerequisite of an IgG antibody value of >650 IU/ml for the diagnosis of viral activity, which was fulfilled in only two of the children. Despite the high rate of indeterminate results, the Enzygnost system is useful in diagnosing acute and past Epstein-Barr virus infection in childhood. For serological diagnosis of viral activity in childhood, a supplementary assay is necessary.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682505      PMCID: PMC88462          DOI: 10.1128/JCM.39.11.3902-3905.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Incidence of heterophil antibody responses in children with infectious mononucleosis.

Authors:  G Fleisher; E T Lennette; G Henle; W Henle
Journal:  J Pediatr       Date:  1979-05       Impact factor: 4.406

Review 2.  The Epstein-Barr virus and EB virus infections in childhood.

Authors:  W A Andiman
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

3.  Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection.

Authors:  S E Straus; G Tosato; G Armstrong; T Lawley; O T Preble; W Henle; R Davey; G Pearson; J Epstein; I Brus
Journal:  Ann Intern Med       Date:  1985-01       Impact factor: 25.391

4.  Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies.

Authors:  J F Jones; C G Ray; L L Minnich; M J Hicks; R Kibler; D O Lucas
Journal:  Ann Intern Med       Date:  1985-01       Impact factor: 25.391

5.  Compact Epstein-Barr virus diagnosis based on a defined antigen mix and specific IgA.

Authors:  H D Dopatka; W Schuy
Journal:  Res Virol       Date:  1996 Jan-Feb

6.  Evaluation of a new reagent for anti-cytomegalovirus and anti-Epstein-Barr virus immunoglobulin G.

Authors:  J Gutierrez; M D Maroto; G Piédrola
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

7.  Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies.

Authors:  A L Bruu; R Hjetland; E Holter; L Mortensen; O Natås; W Petterson; A G Skar; T Skarpaas; T Tjade; B Asjø
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

8.  Primary infection with Epstein-Barr virus in infants in the United States: clinical and serologic observations.

Authors:  G Fleisher; W Henle; G Henle; E T Lennette; R J Biggar
Journal:  J Infect Dis       Date:  1979-05       Impact factor: 5.226

9.  Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection.

Authors:  M Tobi; A Morag; Z Ravid; I Chowers; V Feldman-Weiss; Y Michaeli; E Ben-Chetrit; M Shalit; H Knobler
Journal:  Lancet       Date:  1982-01-09       Impact factor: 79.321

Review 10.  Epstein-Barr virus infection and associated diseases in children. II. Diagnostic and therapeutic strategies.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

View more
  6 in total

1.  Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.

Authors:  J Lupo; R Germi; T Semenova; M Buisson; J M Seigneurin; P Morand
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

2.  Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.

Authors:  Gerson Dierley Keppeke; Minoru Satoh; Maria Lucia Gomes Ferraz; Edward K L Chan; Luís Eduardo C Andrade
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

3.  Expanding the spectrum of neurological disease associated with Epstein-Barr virus activity.

Authors:  M Kleines; J Schiefer; A Stienen; M Blaum; K Ritter; M Häusler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-15       Impact factor: 3.267

4.  Antiviral antibody profiling by high-density protein arrays.

Authors:  Xiaofang Bian; Peter Wiktor; Peter Kahn; Al Brunner; Amritpal Khela; Kailash Karthikeyan; Kristi Barker; Xiaobo Yu; Mitch Magee; Clive H Wasserfall; David Gibson; Madeleine E Rooney; Ji Qiu; Joshua LaBaer
Journal:  Proteomics       Date:  2015-05-15       Impact factor: 3.984

5.  Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers.

Authors:  Susanne Maurmann; Lutz Fricke; Hans-Joachim Wagner; Peter Schlenke; Holger Hennig; Jürgen Steinhoff; Wolfram J Jabs
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

6.  Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation.

Authors:  Jeffrey E Gold; Ramazan A Okyay; Warren E Licht; David J Hurley
Journal:  Pathogens       Date:  2021-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.